PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Inclusion Criteria:

• Willing and able to comply with all scheduled visits, treatment plan, laboratorytests, lifestyle considerations (including contraception requirements), and otherstudy procedures

• Histologically confirmed advanced, recurrent, or metastatic solid tumor malignancywith any mutation of SMARCA4 (dose escalation and combination cohorts) and loss offunction mutation of SMARCA4 (backfill cohorts) by local testing that have eitherprogress on or ineligible for standard of care therapy

• Must have measurable or non-measureable (but evaluable) disease per RECIST v1.1 fordose escalation and combination cohorts

• Must have measureable diseases per RECIST v1.1 for backfill cohort

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Willing to provide either archival or fresh tumor tissue sample

• Adequate organ function (hematology, renal, and hepatic)

Exclusion Criteria:

• Participants with solid tumors with known concomitant SMARCA2 mutation or loss ofprotein expression

• Clinically significant or uncontrolled cardiac disease, uncontrolled electrolytedisorders, uncontrolled or symptomatic central nervous system (CNS) metastases orleptomeningeal disease

• History of another malignancy within 3 years except for adequately treated basalcell or squamous cell skin cancer, superficial bladder cancer, prostateintraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive orindolent malignancies, or malignancies previously treated with curative intent andnot on active therapy or expected to require treatment or recurrence during thestudy

• Concurrent treatment with strong or moderate CYP3A4 inhibitor or inducer